For the millions of adults managing knee osteoarthritis, intra-articular corticosteroid injections have become a go-to bridge between failed oral pain relief and eventual joint replacement — yet the evidence underpinning that clinical habit is far shakier than widespread practice implies. This narrative review, drawing on literature spanning 2000–2026, arrives at a conclusion that demands recalibration of routine practice: corticosteroids may accelerate the very joint deterioration they are meant to temporize.
The review synthesizes available clinical evidence on the efficacy and safety profile of intra-articular corticosteroid (IACS) use specifically in knee osteoarthritis. Its central finding is that meaningful pain relief is largely confined to the short-term window — weeks rather than months — while cumulative or repeated injections are associated with chondrotoxicity, meaning direct toxic effects on cartilage cells. Critically, the authors conclude that long-term IACS use may hasten structural progression of osteoarthritis rather than simply failing to slow it. The review also surveys alternative intra-articular options, suggesting the field is actively seeking replacements.
This finding is not entirely new — a landmark 2017 JAMA randomized trial by McAlindon et al. showed triamcinolone injections every 12 weeks produced measurable cartilage loss over two years without functional benefit — but this review extends the concern to broader clinical patterns. The mechanism likely involves glucocorticoid-induced suppression of chondrocyte metabolism and promotion of apoptosis in an already nutrient-poor joint environment. From a longevity and musculoskeletal healthspan perspective, this matters considerably: cartilage has negligible regenerative capacity, and accelerating its loss narrows the window for conservative management. Key limitations apply — this is a narrative rather than systematic review, meaning selection bias in included studies is possible and no meta-analytic effect sizes are reported. Still, as an expert opinion synthesis, it reinforces a growing clinical consensus that IACS should be treated as a carefully rationed tool, not a repeatable default.